Jump to:  A   |   B   |   C   |   D   |   E   |   F   |   G   |   H   |   I   |   J   |   K   |   L   |   M   |   N   |   O   |   P   |   Q   |   R   |   S   |   T   |   U   |   V   |   W   |   X   |   Y

Cancer Drug Helps Some Kids With Rare Type of Leukemia

Cancer Drug Helps Some Kids With Rare Type of Leukemia

MONDAY, June 5, 2017 (HealthDay News) -- The cancer drug dasatinib shows promise in treating children with chronic myeloid leukemia (CML) caused by the gene BCR-ABL, also known as the Philadelphia chromosome, researchers report.

"Despite the fact that there is a common molecular driver -- BCR-ABL -- for this disease in adults and in children, the manifestation in children is different. Pediatric patients tend to have more aggressive disease," said study senior author Dr. Lia Gore.

She is co-director of the University of Colorado Cancer Center's Hematological Malignancies Program.

"What we saw from the patients we enrolled at Children's Hospital Colorado and around the world was that patients had great disease control, minimal toxicities and were really able to move into normal activities, a normal daily life," Gore said in a university news release.

"One of our long-term patients is in college now and is studying to go on to nursing school as a result of her experience," Gore added.

Chronic myeloid leukemia accounts for 5 percent of all childhood leukemias, with about 150 cases a year in the United States.

Most cancers, including CML, are more common in adults, so it can be hard to enroll enough pediatric cancer patients in a clinical trial, Gore noted. This latest trial is the largest prospective trial of pediatric patients with CML, conducted at 80 medical centers in 18 countries, she said.

Of the 113 child patients in the phase 2 clinical trial, 75 percent of those who had previously failed or could not tolerate an older drug called imatinib (Gleevec) had progression-free survival 48 months after starting treatment with dasatinib (Sprycel).

Among newly diagnosed patients and previously untreated patients, more than 90 percent had progression-free survival at 48 months of treatment, the study authors said.

The study was to be presented Monday at the annual meeting of the American Society for Clinical Oncology, in Chicago. Research presented at meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute has more on chronic myeloid leukemia.

SOURCE: University of Colorado, news release, June 5, 2017

Reviewed Date: --

Find a pediatrician
Hematology and Oncology
Dr. Wilson File
Dr. Eric Lowe
Dr. William Owen
Dr. Linda Pegram
Dr. Katherine Watson
Dr. Eric Werner
Dr. Gary Woods
Health Tips
Helping Kids Get Over their Fears
How Old Is "Old Enough" for Contacts?
Leukemia Quiz
Diseases & Conditions
About Cancer
Alternative Therapy for Cancer
Anatomy of a Child's Brain
Anatomy of the Endocrine System in Children
Anxiety Disorders in Children
Asthma in Children Index
Becker Muscular Dystrophy (BMD) in Children
Bone Marrow Transplant for Children
Brain Tumors in Children
Causes of Cancer
Chemotherapy for Children
Chemotherapy for Children: Side Effects
Coping with a Diagnosis of Cancer in Children
Diagnosing Cancer
Ewing Sarcoma in Children
Hepatitis B (HBV) in Children
Inflammatory and Infectious Musculoskeletal Disorders
Inflammatory and Infectious Neurological Disorders
Inguinal Hernia in Children
Insect Bites and Children
Kidney Transplantation in Children
Leukemia in Children
Meningitis in Children
Mood Disorders in Children and Adolescents
Myasthenia Gravis (MG) in Children
Nutritional Requirements for a Child With Cancer
Osteosarcoma (Osteogenic Sarcoma) in Children
Pediatric Blood Disorders
Posttraumatic Stress Disorder (PTSD) in Children
Preparing the School-Aged Child for Surgery
Schizophrenia in Children
School-Aged Child Nutrition
Sports Safety for Children
Superficial Injuries Overview
Television and Children
The Growing Child: 2-Year-Olds
The Heart
The Kidneys
Treatment for Cancer
Your Child's Asthma
Your Child's Asthma: Flare-ups

Disclaimer: This information is not intended to substitute or replace the professional medical advice you receive from your child's physician. The content provided on this page is for informational purposes only, and was not designed to diagnose or treat a health problem or disease. Please consult your child's physician with any questions or concerns you may have regarding a medical condition.